Dongguk University

Installation Marks the Second ZAP-X System in Korea to Offer the Latest Advance in Non-Surgical Brain Tumor Care GOYANG-SI, South Korea--(BUSINESS WIRE)-- ZAP Surgical Systems, Inc., a global leader in surgical robotics, proudly announces the completion of first patient treatments at Dongguk University Ilsan Hospital using the ZAP-X® Gyroscopic Radiosurgery® platform. This marks the second installation of the ZAP-X system in Korea, signifying a substantial advancement in providing cutting-edge medical care to patients in the Asia-Pacific region. This press release features multimedia. View the full release here: The Vault-Free, Cobalt-Free ZAP-X® Gyroscopic Radiosurgery® Platform at Dongguk University Ilsan Hospital (interior view). (Photo: Business Wire) Stereotactic radiosurgery (SRS) provides a non-invasive and painless treatment option for treating many primary and metastatic brain tumors, as well as other conditions of the head and neck. With outcomes equivalent or superior to traditional open surgeries, SRS typically involves only one to five brief outpatient visits, allowing patients to often resume normal activities on the same day. Historically, the hospital’s radiosurgery patients were treated in the Radiation Oncology department using multi-purpose radiation delivery systems typically employed for breast, lung, and prostate cancers. However, with the addition of the ZAP-X platform, the Neurosurgery department at Dongguk University Ilsan Hospital will now independently lead cranial SRS treatments. The ZAP-X system is exclusively optimized for cranial, head, and neck applications, helping to ensure the highest precision and minimize potential radiation exposure to healthy critical anatomy. Located 60 minutes from Seoul's Incheon International Airport, Dongguk University Ilsan Hospital is a renowned medical institution founded by Dongguk University. With 33 departments, 47 specialized clinics, and 11 specialized centers, the hospital is committed to delivering exceptional patient care through the latest innovations and advanced technology. The ZAP-X system's ground-breaking design utilizes gyroscopic mobility to precisely focus high-dose radiation on targeted tumors from thousands of potential angles, maximizing the preservation of healthy brain tissue and patient cognitive function. Further, its vault-free and cobalt-free features eliminate the requirement for expensive shielded radiation treatment rooms and the management of radioactive isotopes. Dr. Seung-yeob Yang, Professor of Neurosurgery at Dongguk University Ilsan Hospital expressed his enthusiasm, stating, "The ZAP-X system represents a meaningful advancement in our ability to treat primary and metastatic brain tumors, as well as functional disorders such as trigeminal neuralgia. Its precision and non-invasive nature allow us to provide our patients with the best possible care while minimizing side effects and patient downtime." “Together with superior technical capabilities, the ZAP-X platform offered significant advantages over traditional radiation delivery systems. Also, ZAP-X eliminated the need to construct a shielded radiation bunker and allowed for easy installation in our existing outpatient Neurosurgery department,” added Dr. Yang. About ZAP Surgical Systems, Inc. ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler. In addition to being CEO of ZAP, Dr. Adler is Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn. View source version on businesswire.com: Contacts Mark Arnold, ZAP Surgical Systems, Inc. Senior Vice President, Marketing +1 650 492 7797, ext. 101 Email: info@zapsurgical.com Source: ZAP Surgical Systems, Inc. Smart Multimedia Gallery Photo The Vault-Free, Cobalt-Free ZAP-X® Gyroscopic Radiosurgery® Platform at Dongguk University Ilsan Hospital (interior view). (Photo: Business Wire) Photo The Vault-Free, Cobalt-Free ZAP-X® Gyroscopic Radiosurgery® Platform at Dongguk University Ilsan Hospital (exterior view). (Photo: Business Wire) Logo View this news release and multimedia online at:

The study found that using the combination of low PSi and SR had high predictability for mortality 180 days after cardiac arrest Masimo SedLine brain function monitoring. (Credit: Business Wire) Masimo announced that the combination of two SedLine parameters, including patient state index (PSi) and suppression ratio (SR), has shown high predictability for mortality 180 days after cardiac arrest. Dr Tae Youn Kim and colleagues at the Dongguk University College of Medicine and Yonsei University College of Medicine in Korea assessed the potential of two parameters offered by Masimo SedLine brain function monitoring for the prediction of neurological outcomes and long-term survival in post-cardiac arrest ICU patients. Researchers used a multi-modal approach to assess the prognostic accuracy of the two Masimo SedLine parameters as predictors of neurological outcomes, both alone and in combination. The team selected PSi as it is widely used in anesthesiology to determine the degree of procedural sedation, while SR was selected to estimate the percentage of EEG suppression. PSi is derived from EEG. Masimo recruited 103 adult patients between January 2017 and August 2020 who experienced a non-traumatic out-of-hospital cardiac arrest and successfully resuscitated after CPR. They were given targeted temperature management during their ICU stay. Masimo SedLine was used to continuously monitor PSi and SR immediately after ICU admission until 24 hours after return of spontaneous circulation (ROSC). Both parameters have been recorded at one hour intervals Pittsburgh Brain Stem Score (PBSS) and Cerebral Performance Category (CPC) were used to categorise the neurological outcomes. According to the company, the researchers noticed that using either PSi or SR alone had good predictability for poor neurological outcome and the combination of low PSi and SR had high predictability for mortality 180 days after cardiac arrest. The researchers concluded that PSi and SR are good predictors for early neuro-prognostication in post-cardiac arrest patients, said the company. The SedLine brain function monitoring system secured approval from the US Food and Drug Administration (FDA) in January 2018. Featuring an advanced signal processing engine, the system is designed to provide clinicians with a complete picture of the brain.